Trial Profile
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Vamorolone (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors ReveraGen BioPharma
- 28 Apr 2021 Results (new clinical data of 2.5-year treatment outcome) presented in a Santhera Pharmaceuticals media release.
- 22 Sep 2020 According to a Santhera Pharmaceuticals media release, this trial is conducted by the Cooperative International Neuromuscular Research Group (CINRG).
- 22 Sep 2020 Results presented in the Santhera Pharmaceuticals Media Release.